“The supply of Russian-produced lutetium-177 opens up new opportunities for cooperation with our Chinese partners. We hope that it will allow us to increase trade turnover between our countries in the future,” said Maxim Kushnarev, Director General of Isotope JSC.
Lutetium-177 is one of the most promising radionuclides. There are already Lutetium-177-based radiopharmaceuticals registered and used in the treatment of neuroendocrine tumors and prostate cancer. Developments are also underway in a wide range of nosologies (breast cancer, lung cancer, myeloid diseases, skin cancer, kidney cancer, pancreatic cancer, thyroid cancer, colon cancer, etc.).
With Rosatom’s medical radioisotope products, it is possible to carry out about 2.5 million diagnostic and therapeutic procedures in Russia and abroad. Using radiopharmaceuticals in diagnostics helps identify diseases and begin therapy at an early stage.
Background
Isotope JSC is the industry integrator for turnover and promotion of Rosatom’s isotope products, Rosatom’s official supplier of Rosatom’s isotope network products to the international market and the key supplier of the same to the domestic market. The company belongs to Rosatom’s scientific division. Isotope JSC cooperates with 170 foreign companies in 50 countries and with about 600 companies in Russia, including healthcare, manufacturing and research facilities.
In its research and scientific activities, Rosatom is seeking new energy solutions and developing innovative technologies that could improve life quality. Rosatom carries out its research on the basis of its nuclear centers and scientific institutes which constitute a large and important part of the nuclear industry.
Russia is consistently developing its international trade and economic relations with the focus on long-term win-win cooperation, in particular in the supplies of radioisotope products.
